EMA Authorised: Laventair Ellipta (previously Laventair) (umeclidinium bromide;vilanterol) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EU authorises Laventair Ellipta (umeclidinium bromide and vilanterol) for chronic obstructive pulmonary disease; the product is manufactured by GlaxoSmithKline …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Laventair Ellipta
• Umeclidinium bromide (umeclidinium bromide)
• Vilanterol (vilanterol)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 27/08/2025